Genenta Science S.p.A.
GNTA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GNTA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GNTA
Genenta Science S.p.A. (GNTA) is a clinical-stage biotechnology company developing hematopoietic stem cell gene therapies, with its lead candidate Temferon in early-stage trials and no approved products or product revenue to date.
Key risk: No approved products or revenue
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 2 clinical trials for Genenta Science S.p.A..
Genenta Science S.p.A. (GNTA) is a clinical-stage biotechnology company developing hematopoietic stem cell gene therapies, with its lead candidate Temferon in early-stage trials and no approved products or product revenue to date.
- Genenta is a clinical-stage biotechnology company focused on hematopoietic stem cell gene therapies [sec_mda · as of 2025-03-28].
- Lead product candidate is Temferon, which is in preclinical and clinical development [sec · filed 2026-04-01].
- No products have been approved for commercial sale, and the company has not generated any revenue from product sales [sec_mda · as of 2025-03-28].
- As of December 31, 2025, the company reported cash & equivalents of $5.5M, net income of -$6.5M, shareholders' equity of $20.4M, and total debt of $7.6M [sec].
- The company has incurred net losses each year since inception and expects to continue incurring significant operating losses for the foreseeable future [sec · filed 2026-04-01].
What works
- Genenta has advanced its lead candidate Temferon into clinical development, indicating progress in its pipeline [sec · filed 2026-04-01].
- The company has raised gross cash proceeds of approximately €68.5 million through equity and convertible debt securities as of December 31, 2024, demonstrating prior capital market access [sec_mda · as of 2025-03-28].
What to weigh
- All product candidates are in early development, and none have been approved for commercial sale; the company has not demonstrated ability to complete late-stage trials or achieve regulatory approval [sec · filed 2025-03-28].
- The company has incurred net losses each year since inception and expects to continue incurring significant expenses and operating losses for the foreseeable future [sec · filed 2026-04-01].
- Genenta may need additional funding to continue operations; if unable to obtain financing, it may have to significantly curtail, delay, or discontinue development programs [sec · filed 2025-03-28].
- Clinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes [sec · filed 2025-03-28].
From the filings
Quoted directly from source documents.
Genenta is a clinical-stage biotechnology company developing hematopoietic stem cell gene therapies.
“We are a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies”
SEC MD&A · March 28, 2025
No products have been approved for commercial sale and no product revenue has been generated.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · March 28, 2025
The company expects to continue incurring significant expenses and operating losses.
“We expect to continue to incur significant expenses and operating losses for the foreseeable future.”
SEC filings · April 1, 2026
All product candidates are in early development and none have been approved.
“All of our product candidates are in early development, and none have been approved for commercial sale.”
SEC filings · March 28, 2025
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Genenta has no products approved for sale and has not generated any product revenue, relying solely on external financing [sec_mda · as of 2025-03-28].
- Significant operating losses — The company has incurred net losses each year since inception and expects losses to continue, with cash of only $5.5M as of 2025-12-31 [sec].
- Need for additional capital — If unable to obtain funding on a timely basis, Genenta may need to curtail, delay, or discontinue development programs [sec · filed 2025-03-28].
- Early-stage pipeline uncertainty — All product candidates are in early development; clinical trials are lengthy, expensive, and have uncertain outcomes [sec · filed 2025-03-28].
What to watch
- Progress of Temferon in preclinical studies and clinical trials [sec · filed 2026-04-01].
- Ability to secure additional financing or partnerships to fund operations [sec_mda · as of 2026-04-01].
- Any regulatory milestones or updates regarding Temferon or other pipeline candidates [sec · filed 2025-03-28].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Genenta Science S.p.A. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Genenta Science S.p.A. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
12.0 months
D/E 0.46 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$511K
| Holder | Shares | Value |
|---|---|---|
| eurizon capital sgr s.p.a. | 360,000 | $242K |
| alti global, inc. | 200,288 | $135K |
| smartharvest portfolios, llc | 134,447 | $90K |
| xtx topco ltd | 24,527 | $16K |
| morgan stanley | 15,420 | $10K |
| gamma investing llc | 14,288 | $10K |
| simplicity wealth,llc | 12,211 | $8K |
| farther finance advisors, llc | 3 | $2 |
Short Interest
as of May 21, 2026- % of float
- 0.1%
- Days to cover
- 0.3
- Shares short
- 13,319
- Daily short volume (Jul 29, 2026)
- 1.3%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GNTA short interestFrequently asked questions
What is the AI investment thesis for Genenta Science S.p.A.?
Genenta Science S.p.A. (GNTA) is a clinical-stage biotechnology company developing hematopoietic stem cell gene therapies, with its lead candidate Temferon in early-stage trials and no approved products or product revenue to date.
Who is the CEO of Genenta Science S.p.A.?
Mr. Pierluigi Paracchi is the chief executive officer of Genenta Science S.p.A. (GNTA).
Where is Genenta Science S.p.A. headquartered?
Genenta Science S.p.A. (GNTA) is headquartered in Milan, MI, Italy.
What therapeutic areas does Genenta Science S.p.A. focus on?
Genenta Science S.p.A. develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.